REGEN BIOMEDICAL
High quality functional micro tissues
OUR BUSINESS
ReGEN Biomedical focusses on growing large amounts of robust and reproducible small pieces of tissue (micro tissues) for toxicity and pharma screening. Functional micro-tissues present the next step in mimicking patient organs and represent the future of personalized medicine.
We are building expertise on how to assemble the micro-tissues into functional pieces of human organs, so-called macro-tissues. The micro tissues serve as building blocks for regenerative medicine therapies and will be assembled into functional macro-tissues.
Our aim is to fully automate all production platforms and equip them with advanced offline and inline quality control. Today, ReGEN operates at research scale while building the foundation for future regulated and quality-controlled manufacturing. We are developing our facility, automated production platforms, processes, quality control strategy, and quality management system step by step, so we can support partners as they progress from research toward clinical, commercial, or other regulated applications.
The platform technology also enables drug screening applications and ex vivo disease models. Large-scale, reliable production is one of the foundations of a new manufacturing industry around affordable regenerative medicine.
“At ReGEN Biomedical, we are building the foundation for the next generation of regenerative therapies. Our mission goes beyond managing symptoms: we aim to address diseases at their core. By advancing innovative solutions for conditions such as type 1 diabetes, kidney failure, osteoarthritis and heart failure, we are taking meaningful steps toward therapies that can truly transform patients’ lives.”
Dr. Marleen van Nuenen, CEO
WHY NOW?
Regenerative Medicine (RM) aims to repair or restore the function of tissues and organs that can prevent or cure chronic diseases. The social and economic potential is enormous: in terms of years of life gained, lower healthcare costs, emergence of new companies and a new RM industry serving a global healthcare market.
One of the major challenges in availability and affordability for patients is the industrialization of implant production. A key challenge for regenerative medicine is moving from manual, labor-intensive laboratory procedures to scalable automated manufacturing processes that meet high quality and regulatory expectations. ReGEN Biomedical is built to support this transition by developing automated, quality-controlled production platforms designed to help bridge the gap between research-scale production and large-scale manufacturing.
Via RegMed XB the Groeifonds (Growth Fund) aids to to build a regenerative medicine pilot factory. RegMed XB is a partnership of research institutions, governments, provinces, health funds and businesses in the Netherlands and Flanders to develop therapies for chronic diseases, based on stem cells, mini-organs, tissues and smart (bio)materials. The RM factory consists of four pilot plants - four state-of-the-art facilities in Eindhoven, Leiden, Maastricht and Utrecht that co-develop the main production platforms of the pilot factory.
PARTNERS
